FI911330A - 1,4,7,10-tetra-azacyklododekan -butyltrioler, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen. - Google Patents

1,4,7,10-tetra-azacyklododekan -butyltrioler, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen. Download PDF

Info

Publication number
FI911330A
FI911330A FI911330A FI911330A FI911330A FI 911330 A FI911330 A FI 911330A FI 911330 A FI911330 A FI 911330A FI 911330 A FI911330 A FI 911330A FI 911330 A FI911330 A FI 911330A
Authority
FI
Finland
Prior art keywords
butyltrioler
azacyklododekan
aemnen
tetra
foerfarande foer
Prior art date
Application number
FI911330A
Other languages
English (en)
Other versions
FI109695B (fi
FI911330A0 (fi
Inventor
Johannes Platzek
Heinz Gries
Hanns-Joachim Weinmann
Gabriele Schuhmann-Giampieri
Wolf-Ruediger Press
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI911330A0 publication Critical patent/FI911330A0/fi
Publication of FI911330A publication Critical patent/FI911330A/fi
Application granted granted Critical
Publication of FI109695B publication Critical patent/FI109695B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI911330A 1990-03-19 1991-03-19 Diagnostisia 1,4,7,10-tetra-atsasyklododekaanibutyylitrioleja, niiden käyttö diagnostisina aineina ja menetelmä niiden valmistamiseksi FI109695B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4009119 1990-03-19
DE4009119A DE4009119A1 (de) 1990-03-19 1990-03-19 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel

Publications (3)

Publication Number Publication Date
FI911330A0 FI911330A0 (fi) 1991-03-19
FI911330A true FI911330A (fi) 1991-09-20
FI109695B FI109695B (fi) 2002-09-30

Family

ID=6402765

Family Applications (1)

Application Number Title Priority Date Filing Date
FI911330A FI109695B (fi) 1990-03-19 1991-03-19 Diagnostisia 1,4,7,10-tetra-atsasyklododekaanibutyylitrioleja, niiden käyttö diagnostisina aineina ja menetelmä niiden valmistamiseksi

Country Status (17)

Country Link
US (4) US5980864A (fi)
EP (1) EP0448191B1 (fi)
JP (1) JP2968367B2 (fi)
AT (1) ATE124405T1 (fi)
AU (1) AU647091B2 (fi)
CA (1) CA2038493C (fi)
DE (3) DE4009119A1 (fi)
DK (1) DK0448191T3 (fi)
ES (1) ES2074219T3 (fi)
FI (1) FI109695B (fi)
HK (1) HK1002811A1 (fi)
HU (1) HU215964B (fi)
IE (1) IE67643B1 (fi)
IL (1) IL97592A (fi)
NO (2) NO179610C (fi)
NZ (1) NZ237461A (fi)
PT (1) PT97065B (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4140779A1 (de) * 1991-12-06 1993-06-09 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Verfahren zur herstellung von mono-n-substituierten tetraazamakrocyclen
DE4237943C2 (de) * 1992-11-06 1997-10-23 Schering Ag Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
DE4317588C2 (de) * 1993-05-24 1998-04-16 Schering Ag Fluorhaltige makrocyclische Metallkomplexe, Verfahren zu ihrer Herstellung, sowie ihre Verwendung
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
EP0841951A2 (en) * 1995-06-26 1998-05-20 Concat Ltd. Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
DE19646762B4 (de) * 1996-11-04 2004-05-13 Schering Ag Verwendung von Metallverbindungen zur Herstellung von Mitteln zur Strahlentherapie von Tumoren
DE19652387A1 (de) * 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
US20080125344A1 (en) * 2006-11-28 2008-05-29 Daryle Hadley Busch Bleach compositions
US20030017941A1 (en) * 1997-03-07 2003-01-23 The Procter & Gamble Company Catalysts and methods for catalytic oxidation
ZA981883B (en) * 1997-03-07 1998-09-01 Univ Kansas Catalysts and methods for catalytic oxidation
MA24594A1 (fr) 1997-03-07 1999-04-01 Procter & Gamble Compositions de blanchiment
US20050187126A1 (en) * 2002-08-27 2005-08-25 Busch Daryle H. Catalysts and methods for catalytic oxidation
DE19724186C2 (de) * 1997-06-02 2002-07-18 Schering Ag Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe
IT1297035B1 (it) 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
DE19816370B4 (de) * 1998-04-03 2004-09-09 Schering Ag Substituierte Mangan-D02A-Komplexe, diese enthaltende diagnostische Mittel und ihre Verwendung
EP1088559A3 (de) * 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Galenische Formulierungen
DE10064467C2 (de) * 2000-12-15 2002-10-31 Schering Ag Lithium-Komplexe von N-(1-Hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren Herstellung und Verwendung
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
WO2004006934A2 (de) * 2002-07-10 2004-01-22 Hans Robert Kalbitzer 1,4,7,10-tetraazacyclododecane als modulatoren des guanin-nukleotid bindenden roteins zur behandlung von tumoren
US20040048763A1 (en) * 2002-08-27 2004-03-11 The Procter & Gamble Co. Bleach compositions
EP1635878B1 (en) * 2003-06-25 2010-12-29 Guerbet Peptide conjugate for magnetic resonance imaging of matrix metalloproteinases
FR2867473B1 (fr) 2004-03-12 2006-06-23 Guerbet Sa Compose de porphyrines et utilisation a haut champ en irm
CN1993357B (zh) * 2004-07-02 2011-10-19 伯拉考成像股份公司 用于磁共振成像(mri)的含有具有多羟基化取代基的螯合部分的高弛豫造影剂
DE102009053171B4 (de) 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
WO2011054480A1 (de) 2009-11-09 2011-05-12 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung mittels keramischer membran
DE102009057274B4 (de) 2009-12-02 2011-09-01 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung mittels Trioxobicyclo-octan
EP2327395A1 (en) 2009-11-23 2011-06-01 Bracco Imaging S.p.A Process for the preparation of gadobenate dimeglumine complex in a solid form
DE102010013833A1 (de) 2010-03-29 2011-09-29 Bayer Schering Pharma Aktiengesellschaft Herstellung von Gadobutrol mittels Dimethylformamiddimethylacetal
DE102010023105A1 (de) 2010-06-04 2011-12-08 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung im Eintopfverfahren mittels DMF-acetal und N-Methylimidazol
EP2457594A1 (en) 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
PE20141325A1 (es) 2011-04-21 2014-10-08 Bayer Ip Gmbh Preparacion de gadobutrol de alta pureza
RU2743167C2 (ru) 2015-12-10 2021-02-15 Бракко Имэджинг Спа Контрастные агенты
SI3753929T1 (sl) 2015-12-10 2023-01-31 Bracco Imaging Spa Dimerna kontrastna sredstva
CN108779082B (zh) 2016-04-13 2022-08-02 伯拉考成像股份公司 造影剂
IL265536B (en) 2016-09-27 2022-07-01 Bayer Pharma AG A method for the production of a crystalline form of the a modification of calcobuterol
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018108780A1 (en) 2016-12-12 2018-06-21 Bracco Imaging Spa Dimeric contrast agents
EP3392254A1 (en) * 2017-04-20 2018-10-24 Koninklijke Philips N.V. Compounds for use in the diagnosis of a disease
KR101971435B1 (ko) 2017-08-29 2019-04-24 주식회사 엔지켐생명과학 가도부트롤 중간체 및 이를 이용한 가도부트롤의 제조 방법
EP3820853A4 (en) * 2018-07-10 2022-08-17 Biophore India Pharmaceuticals Pvt. Ltd. PROCESS FOR THE PREPARATION OF 2,2',2''-( 10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECAN-1,4 ,7-TRIYL)-TRIACETIC ACID AND THEIR COMPLEXES
KR102167614B1 (ko) * 2018-08-23 2020-10-19 에스티팜 주식회사 가도부트롤의 제조방법
CN114573521B (zh) * 2020-12-01 2023-10-27 威智医药股份有限公司 一种钆布醇及其中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491129A (en) * 1975-06-04 1977-11-09 Guerbet Sa Iodo-benzene derivatives and an x-ray contrast medium containing them
US4284620A (en) * 1979-03-23 1981-08-18 Mallinckrodt, Inc. N-(2-Hydroxyethyl)-2,4,6-triiodo-3,5-bis-(2-keto-L-gulonamido)benzamide and radiological compositions containing same
NO161560C (no) * 1980-04-17 1989-09-06 Univ California Symmetriske trijodisoftaldiamid-derivater og roentgenkontrastmidler inneholdende disse.
DE3150916A1 (de) * 1981-12-18 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel"
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
MX174467B (es) * 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
IT1224416B (it) * 1987-12-24 1990-10-04 Bracco Ind Chimica Spa Chelanti macrociclici e loro chelati
JPH06507904A (ja) * 1991-05-23 1994-09-08 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 磁気共鳴画像形成用の油脂可溶化合物
US5358704A (en) * 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents

Also Published As

Publication number Publication date
IE910902A1 (en) 1991-09-25
JPH05320146A (ja) 1993-12-03
US20060078503A1 (en) 2006-04-13
NO911063D0 (no) 1991-03-18
PT97065A (pt) 1991-10-31
US6951639B2 (en) 2005-10-04
DE10075007I2 (de) 2003-06-12
HK1002811A1 (en) 1998-09-18
FI109695B (fi) 2002-09-30
CA2038493C (en) 2002-07-02
DK0448191T3 (da) 1995-11-20
ATE124405T1 (de) 1995-07-15
ES2074219T3 (es) 1995-09-01
NZ237461A (en) 1993-12-23
HU910874D0 (en) 1991-09-30
AU647091B2 (en) 1994-03-17
IE67643B1 (en) 1996-04-17
IL97592A (en) 1995-10-31
IL97592A0 (en) 1992-06-21
NO179610C (no) 1996-11-13
NO911063L (no) 1991-09-20
DE4009119A1 (de) 1991-09-26
NO179610B (no) 1996-08-05
NO2001003I1 (no) 2001-03-05
AU7361091A (en) 1991-09-19
DE59105815D1 (de) 1995-08-03
EP0448191A1 (de) 1991-09-25
US5980864A (en) 1999-11-09
US20020176823A1 (en) 2002-11-28
EP0448191B1 (de) 1995-06-28
PT97065B (pt) 1998-07-31
CA2038493A1 (en) 1991-09-20
HUT60478A (en) 1992-09-28
HU215964B (hu) 1999-03-29
FI911330A0 (fi) 1991-03-19
US6399043B1 (en) 2002-06-04
JP2968367B2 (ja) 1999-10-25

Similar Documents

Publication Publication Date Title
FI911330A0 (fi) 1,4,7,10-tetra-azacyklododekan -butyltrioler, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen.
FI915282A (fi) Mono-n-substituerade 1,4,7,10-tetra -azacyklododekanderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen.
IT1270882B (it) Oligopeptidi ad attivita' fungicida
DK0618190T3 (da) 9-(Substitueret glycyl)amido-6-(substitueret)-5-hydroxy-6-deoxy-tetracycliner
FI933568A0 (fi) 9-((substituerad glycyl)amido)-6-demetyl-6-deoxitetracykliner
NO954080D0 (no) Amino(tio)eterderivater
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
NO1999018I1 (no) Lamivudin og zidovudin
DK324286D0 (da) 1-substituerede oxindol-3-carboxamider og deres anvendelse som antiinflammatoriske og analgetiske midler
FI852806L (fi) 2-substituerade -1,3-propylidendifosfonatderivat och deras framstaellning.
SE8600017L (sv) Ny forening
FI892675A0 (fi) 2,6-dihalogenpyridin-3 -karboxylsyraderivat och deras framstaellning.
FI930051A (fi) 4,13-dioxabicyklo(8.2.1)tridecenonderivat samt foerfarande och mellanprodukt foer deras framstaellning
ES541780A0 (es) Tetrahidrotienopiridinas
FI874123A0 (fi) Heptanoyl-glu-asp-ala-aminosyra -immunostimulanter.
EP0221493A3 (en) Use of gyrase blocking agents in decontaminating cell cultures infested by mycoplasmas
FI882444A (fi) Substituerade vinylkefalosporiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
FI841293A0 (fi) Iminosulfonamider och foerfarande foer deras framstaellning, dessa foereningar innehaollande farmaceutiska prepara preparat samt deras anvaendning.
FI890482A (fi) B-laktam-antibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel och i laekemedel.
FI934252A0 (fi) 1,5,6,7-tetrahydro-4h-indazol-4-oner innehaollande laekemedel, nya 1,5,6,7-tetrahydro-4h-indazol-4-oner och foerfarande foer deras framstaellning

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20030006

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L207

Extension date: 20130226

PC Transfer of assignment of patent

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT